Related Experiment Video

Updated: May 26, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Mildronate as a regulator of protein expression in a rat model of Parkinson's disease

Sergejs Isajevs1, Darja Isajeva, Ulrika Beitnere

  • 1Department of Pathology, University of Latvia, Riga. Latvia. sergisajevs@inbox.lv

Medicina (Kaunas, Lithuania)
|December 22, 2011
PubMed
Abstract

Insights

Mildronate demonstrates neuroprotective effects in a rat model of Parkinson's disease by regulating key proteins involved in neuronal survival and differentiation. This study highlights mildronate's potential in managing neurodegenerative conditions.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Mildronate, traditionally a cardioprotective agent, exhibits neuroprotective properties.
  • Parkinson's disease (PD) is characterized by the degeneration of nigrostriatal dopaminergic neurons.
  • Key proteins like Hsp70, GDNF, and NCAM are crucial for neuronal survival and differentiation.

Purpose of the Study:

  • To investigate the effect of mildronate on the expression of Hsp70, GDNF, and NCAM in a rat model of PD.
  • To evaluate mildronate's neuroprotective potential against 6-hydroxydopamine (6-OHDA)-induced neurodegeneration.

Main Methods:

  • Parkinson's disease was modeled using unilateral intrastriatal 6-OHDA injections in rats.
  • Mildronate was administered intraperitoneally at varying doses (10, 20, 50 mg/kg) for two weeks prior to 6-OHDA injection.
  • Biomarker expression (Hsp70, GDNF, NCAM) was assessed using immunohistochemistry and Western blot.

Main Results:

  • 6-OHDA reduced Hsp70 and GDNF expression, which was restored by mildronate (20 and 50 mg/kg).
  • Mildronate (50 mg/kg) completely protected against 6-OHDA-induced decrease in striatal NCAM expression.
  • Mildronate reversed 6-OHDA-induced overexpression of NCAM in the substantia nigra.

Conclusions:

  • Mildronate effectively regulates proteins involved in neuro-glial homeostasis.
  • The findings suggest mildronate possesses significant neuroprotective capabilities in the context of Parkinson's disease.
  • Mildronate's ability to modulate key neuronal survival and differentiation markers warrants further investigation for PD treatment.

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...